A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

SIMPLE SUMMARY: Immune checkpoint blockade has had great success over the past decade, but many patients with cancer do not benefit because most immune checkpoint inhibitors only target T cells. Targeting non-T cell populations in the tumor microenvironment (TME) has been shown to affect responses t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Yeejin, Kang, Hwankyu, Yang, Yeongin, Park, Dongsik, Choi, Baejung, Kim, Jeongjun, Kim, Jaeseung, Nam, Kiyean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563311/
https://www.ncbi.nlm.nih.gov/pubmed/36230744
http://dx.doi.org/10.3390/cancers14194821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563311/
https://www.ncbi.nlm.nih.gov/pubmed/36230744
http://dx.doi.org/10.3390/cancers14194821

Ejemplares similares